Arcturus Leaps On COVID-19 Trials And Investor Interest In mRNA
Share Price Soars By 68%
Singapore has granted approval for a Phase I/II trial of Arcturus’s next generation mRNA COVID-19 vaccine candidates, hot on the heels of a similar approval from Vietnam earlier this week. The biotech’s share price duly rocketed, but there may be more at play.
